Related Experiment Video
Updated: Feb 22, 2026
13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
2.8K
Heparin Binding to an Engineered Virus-like Nanoparticle Antagonist.
Ho Yong Cheong1, Myles Groner1, Kevin Hong1
1Department of Chemistry, Occidental College , Los Angeles, California 90041, United States.
Biomacromolecules
|September 27, 2017
Summary
Researchers engineered bacteriophage Qβ virus-like particles (VLPs) to create a safer heparin antagonist. The T18R VLP demonstrated strong heparin-binding affinity, showing potential as a nontoxic alternative to protamine.
Area of Science:
- Biotechnology
- Biophysics
- Virology
Background:
- Heparin anticoagulation requires reversal with protamine, which has acute toxicity.
- Developing safer heparin antagonists is crucial for medical interventions.
Purpose of the Study:
- To engineer bacteriophage Qβ virus-like particles (VLPs) as novel heparin antagonists.
- To evaluate the efficacy and safety of engineered VLPs as alternatives to protamine.
Main Methods:
- Engineered bacteriophage Qβ VLPs with a T18R mutation for heparin binding.
- Utilized molecular modeling for surface potential analysis.
- Employed chromatography, fluorescence binding studies, dynamic light scattering, and biolayer interferometry.
Main Results:
- The T18R VLP exhibited a large, solvent-accessible cationic region, enhancing heparin binding.
- Demonstrated strong heparin interaction with a dissociation constant (Kd) of approximately 1-10 nM.
- Confirmed 1:1 binding stoichiometry and effective heparin antagonism in vitro clotting assays.
Conclusions:
- Engineered T18R VLPs show significant potential as effective and nontoxic heparin antagonists.
- VLPs represent a promising platform for developing safer alternatives to existing anticoagulation reversal agents.
- Further validation supports the clinical applicability of these engineered VLPs.
